Cloning and characterization of mink plasminogen activator inhibitor type 1 (PAI-1) cDNA and the regulation of mink PAI-1 expression at mRNA level by Chuang, Tsung-Hsien
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
1992
Cloning and characterization of mink plasminogen
activator inhibitor type 1 (PAI-1) cDNA and the
regulation of mink PAI-1 expression at mRNA level
Tsung-Hsien Chuang
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Biochemistry Commons, Cell Biology Commons, and the Molecular Biology
Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Chuang, Tsung-Hsien, "Cloning and characterization of mink plasminogen activator inhibitor type 1 (PAI-1) cDNA and the
regulation of mink PAI-1 expression at mRNA level " (1992). Retrospective Theses and Dissertations. 9796.
https://lib.dr.iastate.edu/rtd/9796
UMI 
MICROFILMED 1992 
I 
INFORMATION TO USERS 
This manuscript has been reproduced from the microfilm master. UMI 
films the text directly from the original or copy submitted. Thus, some 
thesis and dissertation copies are in typewriter face, while others may 
be from any type of computer printer. 
The quality of this reproduction is dependent upon the quality of the 
copy submitted. Broken or indistinct print, colored or poor quality 
illustrations and photographs, print bleedthrough, substandard margins, 
and improper alignment can adversely affect reproduction. 
In the unlikely event that the author did not send UMI a complete 
manuscript and there are missing pages, these will be noted. Also, if 
unauthorized copyright material had to be removed, a note will indicate 
the deletion. 
Oversize materials (e.g., maps, drawings, charts) are reproduced by 
sectioning the original, beginning at the upper left-hand corner and 
continuing from left to right in equal sections with small overlaps. Each 
original is also photographed in one exposure and is included in 
reduced form at the back of the book. 
Photographs included in the original manuscript have been reproduced 
xerographically in this copy. Higher quality 6" x 9" black and white 
photographic prints are available for any photographs or illustrations 
appearing in this copy for an additional charge. Contact UMI directly 
to order. 
University Microfilms International 
A Bell & Howell Information Company 
300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA 
313/761-4700 800/521-0600 

Order Number 9220967 
Cloning and characterization of mink plasminogen activator 
inhibitor type 1 (PAI-1) cDNA and the regulation of mink 
PAI-1 expression at mRNA level 
Chuang, Tsung-Hsien, Ph.D. 
Iowa State University, 1992 
U M I  
300 N. Zeeb Rd. 
Ann Arbor, MI 48106 

Cloning and characterization of mink plasminogen 
activator inhibitor type 1 (PAI-1) cDNA and the regulation 
of mink PAI-1 expression at mRNA level 
by 
Tsung-Hsien Chuang 
A Dissertation Submitted to the 
Graduate Faculty in Partial Fulfillment of the 
Requirements for the Degree of 
DOCTOR OF PHILOSOPHY 
Department: Biochemistry and Biophysics 
Major: Molecular, Cellular, and Developmental Biology 
Approved: 
In Charge of Major Work 
For the Gji^duate College 
Iowa State University 
Ames, Iowa 
1992 
Signature was redacted for privacy.
Signature was redacted for privacy.
Signature was redacted for privacy.
Signature was redacted for privacy.
ii 
TABLE OF CONTENTS 
Page 
GENERAL INTRODUCTION 1 
EXPLANATION OF THESIS/DISSERTATION FORMAT 7 
SECTION I. CLONING AND POST-TRANSCRIPTIONAL REGULATION 
OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE I 
GENE IN MINK LUNG CCL64 CELLS 
ABSTRACT 11 
INTRODUCTION 12 
MATERIALS AND METHODS 15 
RESULTS 19 
DISCUSSION 3 2 
REFERENCES 37 
SECTION II. A SYNERGISTIC EFFECT OF TRANSFORMING GROWTH 
FACTOR-BETA AND EPIDERMAL GROWTH FACTOR ON 
THE INDUCTION OF PLASMINOGEN ACTIVATOR 
INHIBITOR TYPE 1 IN MINK LUNG CCL 64 CELLS 
ABSTRACT 47 
INTRODUCTION 48 
MATERIALS AND METHODS 50 
RESULTS 54 
DISCUSSION 63 
REFERENCES 65 
GENERAL SUMMARY 
LITERATURE CITED 
1 
INTRODUCTION 
At least four immunologically distinct plasminogen 
activator inhibitors (PAIs) have been found. Plasminogen 
activator inhibitor type 1 (PAI-1) formerly called the en­
dothelial cell inhibitor (1,2) is found in the a-granules of 
blood platelets (3,4) and in plasma (5,6). Plasminogen acti­
vator inhibitor type 2 (PAI-2) was originally named placental 
type inhibitor (7,8) because of the original source for its 
purification. Plasminogen activator inhibitor type 3 (PAI-3) 
is detected in urine (9) and also found in blood (10). Pro­
tease nexin was purified from culture medium of human fore­
skin fibroblast cells (11). 
These PAIs are members of the SERPIN (serine protease 
inhibitor) family. The function of these PAIs is to act as 
binding proteins of plasminogen activators (PAs). Two dis­
tinct types of plasminogen activators that have been found 
are tissue type plasminogen activator (t-PA), and urokinase 
type plasminogen activator (u-PA)(12). Plasminogen activators 
are serine proteases that convert plasminogen to plasmin. 
Plasmin is a broad spectrum protease that degrades fibrin as 
well as several extracellular matrix proteins (13,14). Thus, 
by controlling the plasminogen and plasmin cascade, the PAIs 
regulate several biological processes such as vascular fibri­
nolysis, cellular migration and tissue remodeling (12,15,16). 
2 
Of the PAIS, PAI-1 is the major inhibitor of PAs. The inter­
action between PAI-1 and PAs is rapid, with a second order 
rate constant between 10^ - 10® M~^s~^ (17) whereas the rate 
constants for interaction between PAI-2 (18), PAI-3 (19) and 
protease nexin (20) is only between 10^-10^ M~^s~^. 
Plasminogen activator inhibitor type 1 is a glycoprotein 
with molecular weight 50 kD. Complementary DNAs of PAI-1 have 
been cloned from human cells (21), rat cells (22) and bovine 
cells (23). The deduced amino acid sequence of human PAI-1 
revealed that this protein contains a signal peptide with 2 3 
amino acids, a mature peptide with 379 amino acids and three 
potential N-glycosylation sites. Synthesis of PAI-1 in cul­
tured cells is highly regulated. Several agents such as 
lipopolysaccharide, interleukin-1, serum, transforming growth 
factor-^, basic fibroblast growth factor, tumor necrosis 
factor, thrombin, dexamethasone and phorbol ester are known 
to induce PAI-1 synthesis in cultured cells (24). 
Transforming growth factor-^s (TGF-^Ss) are a group of 
bifunctional growth factors that can control cell growth and 
differentiation. Distinct molecular forms of TGF-f3 have been 
identified in mammals that are designated TGF-^l, TGF-/32 and 
TGF-)93 (25,26,27,28). Sources for isolating TGF-)3 are plate­
lets, placenta and kidney. TGF-p isolated from these sources 
is a 25 kD protein with two 12.5 kD peptides linked together 
by interchain disulfide bonds. As a growth activator, TGF-p 
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stimulates anchorage independent growth of rat NRK-49F fibro­
blast cell and mouse embryo AKR-2B fibroblast cell (29). 
Anchorage independent growth of NRK-49F cells is stimulated 
synergistically with EGF. As a growth inhibitor, TGF-jS inhib­
its the growth of cultured monkey kidney BSC-1 cells, mink 
lung CCL64 cells and other cell lines, both neoplastic and 
nonneoplastic (30) . In cultured cells, TGF-jS regulates the 
synthesis of many proteins which are important in extracellu­
lar matrix construction and remodeling. Those proteins in­
clude collagenase (31), plasminogen activator (32), plasmino­
gen activator inhibitor (33,34), fibronectin and fibronectin 
receptor (35,36). The mechanism by which TGF-fi regulates the 
synthesis of these proteins is not well understood. However, 
cellular responses to TGF-j3 are mediated by its receptors. 
Three different TGF-)3 receptors have been discovered (37,38) 
with molecular weight of 50-80 kD (type I), 115-140 kD (type 
II) and 280-330 kD (type III) . Transforming growth factor-/31, 
TGF-02 and TGF-j03 bind to all three receptors (39). The 
dissociation constant between TGF-/3 and these receptors is 
about 10-200 pM (37) . The receptors do not possess tyrosine 
kinase activity (40). The ability of type I receptor to bind 
TGF-)9 is increased by expression of type II receptor (41). 
The ability of type II receptor to bind TGF-)9 is increased by 
expression of type III receptor (42). 
Epidermal growth factor (EGF) is a growth factor origi­
nally discovered because of its ability to stimulate the 
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opening of eyelids of newborn mice and to accelerate eruption 
of mouse teeth. This ability is due to the stimulation of 
epidermal growth and keratinization by EGF (43). Male mouse 
salivary glands and human urine are good sources for isolat­
ing EGF. Epidermal growth factor from human was known as 
urogastrone. Both mouse EGF and urogastrone are single pep­
tide chain of 53 amino acids with 70% homology to each other 
(44,45). In cultured cells EGF stimulates the synthesis of 
plasminogen activator (46,47), plasminogen activator inhibi­
tor (35,48), ornithine decarboxylase (49), c-jun and c-fos 
gene products (50,51). The effects of EGF are mediated by the 
EGF receptor which is a 170 kD transmembrane glycoprotein 
with 1180 amino acids. The EGF receptor contains an intracel­
lular tyrosine kinase domain. Stimulation of this kinase 
activity by EGF leads to its autophosphorylation and to the 
phosphorylation of various other cellular substrates. 
12-O-tetradecanoylphorbol-13-acetate (TPA) is one of a 
group of chemical compounds known as tumor-promoting phorbol 
esters. The biological activity of phorbol esters includes 
influencing the state of cell differentiation, proliferation 
and the expression of specific genes (52,53,54). As an ana­
logue of diaceylglycerol, TPA activates the calcium and 
phospholipid dependent protein kinase C (55). A TPA response 
element (TRE) in the 5•-regulatory region of genes has been 
identified (56,57,58) with a consensus sequence 5'-
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TGA(C/G)TCA-3'. Activation of genes through this element is 
mediated by binding of the AP-1 complex, which is a dimer of 
the protooncogene products of c-fos and c-jun. The human PAI-
1 gene has no TRE consensus sequence (59,60) but has a se­
quence in which six of seven nucleotides are conserved 
(GGAGTCA). This sequence is located at position -672 to -666 
upstream of the PAI-1 CAP sites. Two segments which confer 
TGF-)S inducibility on the PAI-1 gene are -791 to -546 and 
-328 to -187 upstream of the CAP sites (61). The TRE-like 
sequence is localized in the former region. 
Previous studies from this laboratory showed that the 
synthesis of PAI-1 is induced by TGF-)3 and TPA in different 
cell lines such as African green monkey kidney epithelial 
BSC-1 cells, rat kidney NRK cells, mouse embryo AKR-2B cells 
and mink lung epithelial CCL64 cells (34) . In mink lung CCL64 
cells PAI-1 is induced by EGF, TGF-^ and TPA. Transforming 
growth factor-^ and EGF act synergistically to increase the 
level of PAI-1. The synergistic effect was also observed in 
human hepatoma Hep G2 cells (62). 
To study the synergistic effect and the mechanisms by 
which the PAI-1 gene is regulated in mink lung CCL64 cells, I 
tested the following hypothesis; the expression of PAI-1 gene 
is regulated at the mRNA level by altering the transcription­
al activity of the PAI-1 gene and by altering the stability 
of PAI-1 mRNA. 
Growth factors and tumor promoters can increase tran-
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scriptional activity and mRNA stability of inducible genes in 
cultured cells. For example epidermal growth factor stabi­
lizes the mRNA of the EGF receptor, /3-tubulin and /9-actin in 
cultured human KB epidermal carcinoma cells (63). Transform­
ing growth factor-# increases the steady state level of type 
1 procollagen and fibronectin mRNA by acting at the post-
transcriptional level in cultured human dermal fibroblasts 
(64). An increase in transcriptional activity is responsible 
for the induction of PAI-1 in bovine aortic endothelial cells 
(65), human rhabdomyosarcoma cells (66). 
In the present studies, the accumulation of PAI-1 mRNA, 
the half life of PAI-1 mRNA, and the transcriptional activity 
of the PAI-1 gene were determined in mink lung CCL64 epithe­
lial cells treated with EGF, TGF-)S, EGF plus TGF-p or TPA by 
using a cloned mink PAI-1 cDNA as a probe. The results indi­
cated that TGF-)3 increases the rate of PAI-1 gene transcrip­
tion and EGF stabilizes PAI-1 mRNA. The combination of the 
effect of TGF-)3 and EGF result in a synergistic effect on 
PAI-1 expression. The TPA induced PAI-1 mRNA has a fast 
turnover rate with half life about 25 min. The fast degrada­
tion rate causes a rapid decrease of accumulation in PAI-1 
mRNA and PAI-1 protein in these cells after the transcription 
rate decreases. 
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EXPLANATION OF THESIS/DISSERTATION FORMAT 
An alternate format as outlined in the Iowa State Uni­
versity Graduate College Thesis Manual is used for this 
dissertation. This dissertation is separated into four parts: 
Introduction, Section I, Section II and Summary. The intro­
duction gives a brief description of those proteins and 
growth factors that were studied in this research project and 
provides a background for the research. Section I, " Cloning 
and post-transcriptional regulation of mink plasminogen 
activator inhibitor type 1 gene in mink lung CCL64 cells " 
describes the procedures for mink PAI-1 cDNA cloning and the 
characterization of the mink PAI-1 clone. The post-transcrip­
tional regulation of 12-0-tetradecanoylphorbol-13-acetate 
induced PAI-1 mRNA is also described in this section. Section 
II, "A synergistic effect of transforming growth factor-beta 
and epidermal growth factor on the induction of plasminogen 
activator inhibitor type 1 in mink lung COL 64 epithelial 
cells" provides an insight into the mechanism by which 
induction of PAI-1 in mink lung CCL 64 cells is synergisti-
cally regulated. Coauthor of section I, Dr. Richard T. Hamil­
ton, is a faculty of the Department of Zoology and Genetics 
of Iowa State University. He was responsible for helping me 
in the cloning of the PAI-1 cDNA. Coauthor of section I and 
II, Dr. Frederic W. Thalacker, was a graduate student in our 
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laboratory. He contributed the results showing the regulation 
of the PAI-1 protein. The summary discusses the conclusions 
of my dissertation. The references in each section of the 
dissertation follow the format of the journal to which the 
paper will be submitted. 
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SECTION I. 
CLONING AND POST-TRANSCRIPTIONAL REGULATION OF 
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 IN 
MINK LUNG CCL64 EPITHELIAL CELLS 
10 
Cloning and Post-transcriptional Regulation of Plasminogen 
Activator Inhibitor Type 1 gene in Mink Lung CCL64 Cells 
Tsung-Hsien Chuang^'^. Frederic W. Thalacker^'3,4 
Richard T. Hamilton^'^, Marit Nilsen-Hamilton^/3/5 
Department of^Biochemistry and Biophysics, 
and ^Zoology and Genetics, 
and the ^ Molecular, Cellular and Developmental Biology 
Program, Iowa State University, Ames, lA 50011. 
^Current Address. Bioscience Research Laboratory,State Uni­
versity Station. Fargo, ND58105. 
^Communicating Author. 
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INTRODUCTION 
Proteolytic degradation of the extracellular matrix that 
surrounds cells is associated with biological processes such 
as fibrinolysis, cellular migration, tissue remodeling, and 
tumor metastasis (10, 12, 30). One of the mechanisms which 
has been implicated in the proteolytic process is the plas­
minogen activator/plasmin system (44) . Two distinct groups of 
plasminogen activators, urokinase-type plasminogen activator 
(u-PA) and tissue-type plasminogen activator (t-PA), convert 
the inactive zymogen plasminogen into plasmin. A broad spec­
trum serine protease, plasmin degrades fibrin and extracellu­
lar matrix proteins. Both u-PA and t-PA are negatively regu­
lated by plasminogen activator inhibitor type 1 (PAI-1). The 
inhibition is rapid with a second-order rate constant between 
10^-10® M~^s~^ (17). Therefore, the regulation of PAI-1 
expression is likely to be important in controlling these 
biological processes. 
PAI-1 is a glycoprotein with a molecular weight of 50 kD 
that is present in plasma and platelets (8, 14). In a variety 
of cultured cells, the production of PAI-1 is modulated by 
different agents. For example transforming growth factor-# 
(TGF-0), fibroblast growth factor (FGF), lipopolysaccharide 
(LPS) and interleukin induce the synthesis of PAI-1 in en­
dothelial cells (8, 13, 33, 37). Transforming growth factor-
13 
j0, dexamethasone and hydrocortisone stimulate the production 
of PAI-l in fibroblast cells (9, 46, 20). T!GF-(3, epidermal 
growth factor (EGF) and 12-0-tetradecanoylphorbol-13-acetate 
(TPA) increase the secretion of PAI-1 in epithelial cells and 
hepatoma cells (46, 20, 22). Synthesis of PAI-1 in these 
cells is generally preceded by an increase in the steady 
state level of PAI-1 mRNA. Evidence has been provided that 
transcriptional regulation is responsible for the stimulatory 
effect on PAI-1 induction. Transforming growth factor-^ was 
also found to stabilize PAI-1 mRNA in human hepatoma cells 
(48) . 
In previous studies (46), we found that the synthesis of 
PAI-1 is regulated by TPA, TGF-j3, and EGF in mink lung CCL64 
epithelial cells. The rate of production of secreted PAI-1 
reaches a maximum between 5 to 7 hours after the cells are 
treated with TGF-j3 and then declines rapidly. Compared to 
that reported in bovine aortic endothelial cells (36), human 
rhabdomyosarcoma cells (24) and human WI-38 lung fibroblast 
cells (23) , the rate of accumulation and decline of PAI-1 
mRNA in mink lung CCL64 epithelial cells is rapid. 
In these studies, it was found that PAI-1 mRNA accumu­
lates rapidly after the addition of TPA and reaches a maximum 
at 3 hours after TPA addition. The PAI-1 mRNA level then 
declines rapidly to the basal level at 7 hours after TPA 
addition. The brief period of PAI-1 gene expression reflects 
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an increase in gene expression and a fast turn over rate of 
PAI-1 itiRNA. The half-life of PAI-1 itiRNA was measured to be 25 
min. Degradation of PAI-1 mRNA was retarded by cycloheximide 
and actinomycin D. Messenger RNA of PAI-1 in mink lung CCL64 
cells shares several common features with mRNA of proto-
oncogene c-fos and c-myc (41, 49). These mRNAs are inducible, 
rapidly degraded and stabilized by cycloheximide and actino­
mycin D. A GU-rich sequence was identified from the 3'-
untranslated region of the PAI-1 mRNA. This sequence in 3' 
LTR of type 1 human T cell leukemia virus was reported to 
directed the cleavage of viral pre-mRNA (1). Another region 
of 120 bp that is highly conserved between PAI-1 mRNAs from 
different species was also identified. It is expected that 
these regions might be important in regulating turnover of 
PAI-1 mRNA. 
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MATERIALS AND METHODS 
Cell culture : Mink lung CCL64 epithelial cells (a gift from 
Dr. Robert Holley) were routinely cultured in Dulbecco-Vogt's 
modified Eagle's medium (DME) containing 0.45% glucose, 10% 
calf serum, 10 unit/ml penicillin and 10 jug/ml streptomycin 
at 37°C in water saturated atmosphere with 13% COg in air. 
For experiments, cells were plated in DME with 10 % calf 
serum. Once confluent, the medium was changed to DME with 
0.2% calf serum and the cells incubated for another 24 hours 
before addition of TPA (10 ng/ml; Sigma). 
Preparation of RNA: For harvest of cells, cell culture medium 
was aspirated and cells were washed twice in Tris-buffered 
salts (0.14 M NaCl, 5.0 mM KCl, 0.68 mM CaClg, 0.49 mM MgClg, 
0.70 mM NagHPO^, 25 mM Tris-HCl pH 7.1). After scraping the 
cells into 4 M guanidinium isocyanate, 25 mM sodium acetate 
pH 6, the total cellular RNA was separated from the cell 
lysate by centrifugation through a cushion of 5.7 M cesium 
chloride, 25 mM sodium acetate pH 6 (6), at 195,000 x g for 
18 hours. Poly(A+)-mRNA was prepared by affinity chromatogra­
phy on oligo(dT)-cellulose (4). All the solutions for RNA 
preparation were made with diethylpyrocarbonate treated 
water. 
cDNA Cloning and Sequencing: A mink cDNA library with approx­
imately 1 X 10^ individual clones was constructed in the Zap 
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II vector (Stratagene) with poly(A^) itiRNA prepared from cul­
tured TPA stimulated mink lung epithelial CCL64 cells. After 
amplification, the library was screened with radiolabeled 
human PAI-1 cDNA (3) (EcoRl-Bgl II fragment; specific activi­
ty 1 x 10® cpm/jug) in a hybridization buffer (40% formamide, 
7% SDS, 1% polyethylene glycol MW=20000, 0.25% non-fat milk, 
0.6 M NaCl, 4 mM EDTA-Na2, 50 /xg/ml salmon sperm DNA, 40 mM 
NaHgPO^ pH 7.5). Positive phage clones were converted into 
the phagemid form in the Bluescript SK(-) vector by in vivo 
excision (40). Plasmids were isolated and the size of the 
cDNA inserts were determined by restriction enzyme digestion 
and analysis by agarose gel electrophoresis. Nested deletions 
from both strands were constructed using exonuclease III and 
mung bean nuclease digestions (Stratagene protocol). Sequenc­
ing was performed from double stranded plasmid DNA by the 
dideoxy chain termination method (34) and the data was ana­
lyzed with the aid of computer sequence analysis program (GCG 
package) designed by Genetics Computer Group of the Universi­
ty of Wisconsin (11) . 
r^^SI-Methionine labeling and SDS-polvacrvlamide gel electro­
phoresis; Cells were plated on 24 wells (1.6 cm diameter/ 
well) tissue culture dishes with DME medium containing 0.2% 
calf serum. One or two days later, after cell attachment, the 
medium was replaced with fresh medium and TPA was added about 
24 hours later. After the indicated incubation time, the 
17 
cells were labeled with [^^S]-methionine (60-200 jitCi/ml, 
Amersham). The labeling medium was collected, the cell were 
rinsed once with Tris-buffered salts and lysed with NP-40 
buffer (0.5% Nonidet P-40, 1 mM phenylmethylsulfonylfluoride, 
100 Kallikrein inactivator units of aprotinin/ml, 10 mM Tris-
HCl pH 7.1). The cell lysate was separated into NP-40 soluble 
and insoluble fractions by centrifiguation at 3000 X g for 20 
min. The [^^S]-methionine labeled samples were resolved by 
7.5% - 15% gradient SDS polyacrylamide gel electrophoresis 
(27). Fluorography and densitometric measurements were used 
to determine the amount of [^^S]-methionine incorporated into 
each protein band. The value of the area under the peak was 
divided by the amount of acid insoluble [^^S]-methionine 
radioactivity in the NP-40 soluble fraction so that the 
results from the densitometer were normalized with the rate 
of [^^S]-methionine incorporation into cellular proteins. 
Northern Blot and Hvbridization; Fractionation of RNA on 1% 
agarose-formaldehyde gel was performed by using MOPS buffer 
(20 mM 3-[N-morpholino]propanesulfonic acid, 1 mM EDTA, 5 mM 
sodium acetate pH 6) as a running buffer. Northern blots were 
performed by transferring the RNA to nylon membranes (Zeta 
probe, from Bio-Rad) with 50 mM sodium hydroxide solution. 
RNA on the blots was hybridized with radiolabeled mink PAI-1 
probe for 18 hours at 47°C in hybridization buffer. The blots 
were washed to a final stringency 30 mM NaCl, 3 mM sodium 
citrate, 0.2% SDS twice for 15 min at 47°C and exposed to 
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Kodak XAR film at -75°C with intensifying screens. To evaluate 
the relative loading of RNA samples, the blots were first 
stripped by incubating with 0.1 % SDS, 15 mM NaCl, 1.5 mM 
sodium citrate, 30 min at 80° twice and then rehybridized 
with radiolabelled 18 S ribosomal RNA probe (15). The densi­
ties of autoradiographic signals were quantified by scanning 
densitometry (Zenith model 504 XL). The relative densities of 
individual bands from PAI-1 mRNA were normalized with the 
relative densities of 18 S ribosomal RNA in each samples. 
Nucleotide sequence accession number: The mink PAI-1 cDNA 
sequence has been submitted to the GenBank/EMBL data bank 
under accession number X58541. 
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RESULTS 
Cloning of mink PAI-1 cDNA; Fourteen positive clones were 
isolated by screening 4 X 10^ phages from the amplified mink 
cDNA library with radiolabeled human PAI-1 cDNA fragment. A 
single clone with an insert size of 3 kb was chosen for 
further analysis. The nucleotide sequence of the mink PAI-1 
cDNA is shown in figure 1. This cDNA codes for a 68 bp 5'-
nontranslated sequence, a 1200 bp translational open reading 
frame, and a 1720 bp 3'-nontranslated region. The in-frame 
coding region of mink PAI-1 cDNA is translated into a 400 
amino acid sequence (Fig. 1) which includes a leader peptide 
of 21 amino acids and a mature peptide of 379 amino acids. A 
comparison of the leader peptides of mink PAI-1 with those of 
human, bovine, rat and mouse PAI-1, showed that mink PAI-1 
lacks two amino acids found in PAI-1 of the other species 
(Fig. 2). Because mink PAI-1 is secreted into culture medium 
by mink lung CCL64 cells (46), the missing two amino acids 
are obviously not essential for secretion of PAI-1. As with 
the other PAI-ls, there is no cysteine in the mature mink 
PAI-1 peptide. Mink PAI-1 has three potential N-glycosylation 
sites (Fig. 1) which are located at the same positions in the 
peptide sequence as in the human PAI-1 sequence. The entire 
amino acid sequence of mink PAI-1 is 86%, 87%, 79%, 77% 
identical to human (16), bovine (25), mouse (28), and rat 
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(50) PAI-1, respectively. 
In the 1.72 kb 3•-nontranslated region, a 120-bp se­
quence was identified that is highly conserved in PAI-1 mRNAs 
from different species (Table 1). This region in the 3'-
untranslated segment of PAI-1 mRNA has been previously re­
ported to be more than 90% identical in nucleotide sequence 
between rat and human PAI-1 mRNAs (50). When the comparison 
of these regions is extended to bovine, mouse, human, and rat 
PAI-1 mRNAs the sequence reported shows between 88% and 95 % 
identity to the species listed on Table 1 with the equivalent 
mink sequence. A GU-rich region (2769-GUUCUUUGUUUGUUUGUUU-
2787) was also identified in the 3' end of the PAI-1 mRNA 
which is not conserved in PAI-1 mRNA from other species but 
is highly conserved with the GU-rich region (605-GUCUUUGUUU-
GUUUCGUUU-623) on type 1 human T cell leukemia virus 3' LTR. 
The T-cell leukemia virus LTR GU-rich region directs its pre-
mRNA cleavage and facilitates polyadenylation (1). 
Regulation of PAI-1 expression: TPA stimulation of PAI-1 
synthesis in CCL64 cells was studied with [^^S]-methionine 
labeling and analysis by SDS-polyacrylamide electrophoresis. 
A 48 kD protein was recognized as PAI-1 by its molecular 
weight and its ability to be immunoprecipitated with an 
antibody made against bovine PAI-1 (46). The results show 
that the production of secreted PAI-1 protein increased 
shortly after TPA stimulation and reached a maximum at 6-10 
21 
hours. The production of PAI-1 then declined rapidly and 
returned to the basal level after 18 hours (Figure 3). The 
profile of TPA induced PAI-1 production is similar to the 
profile for TGF-)3 induced PAI-1 synthesis (46) in which the 
maximum production rate occurred about 6 hour after induction 
with the rate declining to basal level after 18 hour. The 
time course of PAI-1 mRNA accumulation was determined (Figure 
3). The PAI-1 transcripts were barely detectable 0.5 hours 
after TPA addition and reached maximal accumulation 3 hours 
after TPA addition. The level of PAI-1 mRNA then declined 
rapidly and reached its basal level after 7 hour. 
Degradation of PAI-1 mRNA; CCL64 cells were incubated with 
TPA for two hours to induce the transcription of PAI-1 gene. 
After blocking further transcription with cordycepin, total 
RNA was isolated at different times and analyzed by Northern 
blotting. The result (Figure 4) shows that PAI-1 mRNA in the 
CCL64 cells has a half-life of 25 min. Cycloheximide treat­
ment was observed to stabilize PAI-1 mRNA in the cordycepin 
treated cells. Actinomycin D, an agent usually used to block 
transcription by its ability to intercalate with GC base 
pairs of DNA, also stabilized PAI-1 mRNA (Figure 4). The 
stabilization effect of actinomycin D was also observed when 
in combination with cordycepin (Figure 4). 
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TABLE 1 
Comparion of the nucleotide sequence of the high conserved 
3•-nontranslation region of PAI-1 mRNA from different spe­
cies. 
The number in parentheses indicate the starting and 
termination nucleotide numbers of the conserved sequence. 
Identity of the sequences were analyzed by the computer 
program (11). 
identity mink PAI-1 (2413-2532) 
bovine PAI-1 (2446-2565) 
human PAI-1 (2437-2556) 
mouse PAI-1 (2446-2565) 
93.3% 
95.0% 
89.2% 
rat PAI-1 (2504-2623) 88.1% 
Figure 1. The nucleotide sequence and deduced amino acid 
sequence of mink PAI-1 cDNA: The single letter 
code is used for the amino acid sequence. The 
arrow indicates the leader peptide cleavage 
site. The asterisks(*) indicates potential 
N-glycosylation site. The active center is 
boxed. The region with 120 bp high conserved 
nucleotide sequence is underlined. The GT rich 
region is doubly underlined and the polyadeny-
lation signal is indicated by five asterisks 
above the letter code for the bases. 
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1 TCGCCACCGTCAGCAGCAGCACCAGCAGSACAQACCAGCAATCACAAGGCACCTTTGAGAACTTCAGG 
H Q M S T V C L A L G L A L V F G E A S  A * S  Y L H E T R A A  
69 ATGCAGATGTCTACAGTCTGCCTTGCCCTGGGCCTGGCCCTTGTCTTTGGTGAAGCATCGGCCTCCTACCTCCACGAGACCCGGGCAGCG 
E L A T O F G V K V F K Q V A Q A S I C O R N M V F S P Y G L  
159 GAACTGGCCACACACTTCGGAGTGAAAGTGTTTAAGCAGGTGGCACAGGCCTCCAAGGACCGCAACATGGTTTTTTCCCCCTATGGGTTG 
A S V L A M L Q L T T A G E T R Q Q I Q E A M R F Q I D E K  
249 GCCTCTGTCCTGGCCATGTTGCAGCTGACCACAGCAGGAGAGACCCGGCAGCAGATCCAAGAGCCCATGCGGTTCCAGATTGATGAGAAG 
G M A P A L R O L Y K E L M G P U H K D E I S T A O A l  F V  
339 GGCATGGCACCTGCCCTCCGCCAACTGTACAAGGAACTCATGGGGCCGTGGAACAAGGATGAGATCAGTACCGCGGACGCCATCTTCGTC 
Q R O L K L V H G F H P Y F F R L F Q T T V K Q V D F S E V  
429 CAGCGGGATTTGAAGCTGGTCCACGGCTTCATGCCCTACTTCTTCAGGCTGTTCCAAACCACACTCAAGCAGGTGGACTTCTCAGAGGTG 
E R A R F I I N D U V K R H T K G H I G D L L G R G T V D O  
519 GAGAGAGCCAGGTTCATCATCAACGACTGGGTCAAGCGACACACAAAAGGCATGATTGGCGACCTGCTGGGCAGAGGCACTGTGGACCAG 
L T R L H L V H A L Y F N G Q U K T P F P K S G T H H R L F  
609 CTGACGCGTCTGATGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACCCCTTTCCCCAAGTCGGGCACCCACCACCGCCTCTTC 
H K S D G S T V S V P M H A  O T M K F N Y T E F S T P E G R  
699 CACAAATCTGATGGCAGCACCGTCTCCGTGCCCATGATGGCTCAGACCAACAAGTTCAACTACACCGAGTTTTCTACCCCCGAGGGCCGT 
Y Y D I L E L P Y H G D T L S M F I A A P Y E K D V P L S A  
789 TATTACGACATCCTGGAACTGCCCTATCACGGAGACACGCTCAGCATGTTCATTGCTGCTCCCTATGAAAAAGACGTGCCTCTTTCTGCC 
L T N I L D A Q L I S Q W K G N N T R R L R L L V L P K F S  
879 CTCACCAACATCCTGGATGCCCAGCTCATCAGCCAGTGGAAAGGGAATATGACCAGACGGCTCCGCCTCCTGGTTCTGCCCAAGTTCTCC 
L E S E V N L R G P L E H L G N T O M F R P N Q A D F S S L  
969 CTGGAGAGCGAAGTCAACCTCCGGGGACCCCTCGAGAACTTGGGGATGACTGACATGTTCAGGCCAAACCAGGCAGACTTCTCCAGTCTT 
S D Q E A L Y V S O A L Q K V K I E V H E S G T V A S S S T  
1059 TCAGATCAAGAGGCACTGTACGTGTCCCAGGCGCTGCAGAAAGTGAAAATCCAGGTGAACGAGAGCGGCACGGTGGCGTCCTCCTCTACA 
A  I  I  V  S  A  ;  R  M  >  P E E I  I H O R P F L F V V R H M P T G T  
1149 GCCATCATCGTCTCAGCCCGAATGGCCCCCGAGGAGATCATCATGGACAGACCCTTCCTCTTCGTGGTGCGGCACAACCCCACAGGAACG 
V L F H G Q V N E P *  
1239 GTCCTTTTCATGGGCCAAGTGATGGAACCCTGACCGCGAGCACAGCAGCCCTCATCTGGGACAGAACTGGAGATACATCCAAGAAGAAGG 
1329 AACTCTAAAGGAACAAAATATATATTTTTTCATTAATTTTTCTGGAGAAAAAGAAGTCATTTGCCCTTTAGGGAAAAACAAAACAAAACA 
1419 AAAACCAAAAAAACAAAAAAAGGTAAATCTTTCGAATCTGCATCCCAGACCTCAGCCTCTCCCAGGAATGGGAAAGAGGACCTTTCAGTA 
1509 AAACTCCACGGTGGAGCCCCCCGGAGAGACCTCCGAAGCACAGCTGCGTCTCCACACCAGACTGCAAACCTCAGACAACCACTGGCGCAG 
1599 TGCTCTGCCCATCCGGCTCTGCAGACCTGGACCCCGCCGAGACCCCGGCAGCATGGCACCCCAAGGCTTGCGGGAGCTTTTGTGTGCTTG 
1689 GTGGAAACGATTTGTGTTCCAGGCACGTAGCTGTCACTCCTGCACTGTCTGCCACTGCTGAGGAGGCTGGCGGCGGGCCAAAGAAGGCCA 
1779 GTGGGAGAGGCACCCTTTCTGTTCGAGGTCTGTGCCGCCCCGATCG6ACGCTCTCCCCGCCCCGGGCGGAGACCCGCCCTGACCTGGCCG 
1869 TGGCCCTCCCCAGAAACAGTGTGCATATATTATTTTGGAGTGTAGGTGACTTGTTTACTCATAGGAGCAGGTTTCTGCTTCCCACTAACT 
1959 TTATTTTGCAGGAATGGAGGAATAGAAGTGAGATGCGTGCCTGGTTCTTCGCTCTAATCTCCCGGTGGGGAGGGTGGGATGCCAGGGGTG 
2049 TGCTTGGGTATTTAATCACATCCTTGTCCTTGTGTGCTTGTGAGAGAGAAAGAGGACTCTCAAGAAAAACGTAGTCTATGTATTTGCTTG 
2139 TCATGTTCCCTGGTGGTTTGTGTCTTGCCTCTCAGGAGTCTGGCCCCCTGACTAGCTGCCCCTCTGGGCGGCAAGCGTGGTGGGACCCAC 
2229 ACTGCCCCCTTGTGGCTTCCTGAGCCCCGTGGTTCCTCTCCCGTCCTGGCCCTTCCACTCCATGGAGAAGACCCCCGTCAAGATGATCTA 
2319 ACTTTAGGGACCAAAAGGATGTGGTGGGTCAGAGAGATTACAGCGAGGACAGCATGCTTTCAAAATTTTCCAATATATTTAGGAACAGGA 
2409 GAGCAAGGGGCTGCACGACCTAACAGGACAGAACTTTCCCCAATTACAGGGTGATTCACAGCC6CATTCCTCACTCATTTCCATCTGTCA 
2499 TTTCCGGCTGCTGTGTGCGAGCAGTGGACACGTGAGAGAGGGGGAGAGAGATTGACTGAGAGAGACACGACAATGAGAGAGACCACGAGC 
2589 TCCGACTTAACTACCCTCCCTAGATAATCTTTCTGAAAGCCAACGAGCTAGGGGGCATCGTATGAAGACCCAGTTTGTTGAAGAATTGCA 
2679 CATAGATGTTGAATGAATGAATGTAACCCAAACAGGACCCTAACCGCCTCCCCCCCAAACCCCCCCATCCCTCTTCAGTGAAAAAT|nT 
2769 GTTÇnmr^mGTTmçnAATGCACTGGACAGTGACAGCTACACACAGTCCCCATAAGGATACCCAAGTGTGGGGTCCAACATT 
2859 CTTGAAGTTGTGTTGAATCATATGCTTTTTCACTTTTGATATATAAACAAGCAAAATATTTTTrAAAAATÂÂTÂÂAATAAGTTAATTAAA 
2949 ATATAAAAAAAAAAAAAAAAAA 
30 
60 
90 
120 
150 
180 
210 
240 
270 
300 
330 
360 
390 
400 
Figure 2. Comparision of the leader peptides of the PAI-1 
from different species. The numbers indicate the 
amino acid position. 
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mink PAI-1 
human PAI-1 
bovine PAI-1 
rat PAI-1 
mouse PAI-1 
1 MQMST..VCLALGLALVFGEASA 21 
1 MQMSPALTCLVLGLALVFGEGSA 23 
1 MRMSPVFACLALGLALIFGEGSA 23 
1 MQMSSALTCLTLGLVLVFGKGFA 23 
1 MQMSSALACLILGLVLVSGKGFT 23 
Figure 3. Regulation of PAI-1 expression by TPA. 
A; Time course of PAI-1 protein synthesis: CCL64 
cells were plated in DME medium with 0.2% calf 
serum. Twenty four hours later TPA (10 ng/ml) 
was added to the cells. The cells were labeled 
with [^^S]-methonine for 4 hrs, beginning 
from 0 to 18 hrs after addition of TPA. The 
symbols in the figure are located at the middle 
point of the labeling periods. 
Time course of PAI-1 mRNA accumulation: CCL64 
cells were incubulated in DME medium with 0.2% 
calf serum. After treated with 10 ng/ml TPA, 
total RNA was isolated from cells at various 
times. Total RNA (10 ng) from specific time 
points was resolved by formaldehyde-agarose gel 
electrophoresis. After blotting to nylon 
membranes, the RNAs were probed with ^^P-labeled 
PAI-1 and ^^P-labeled 18S ribosomal RNA probes. 
The relative intensities of the PAI-1 mRNA and 
IBS ribosomal RNA bands on autoradiograms were 
analyzed by laser densitometry. To control for 
the loading of total RNA, the intensity of 
PAI-1 mRNA was normalized to the intensity of IBS 
ribosomal RNA. 
The results are representative of two separate 
experiments. 
Protein (-i-); mRNA (-0-). 
B: Northern blot exposures that were used to obtain 
the data shown in 3A. 
PERCENTAGE OF MAXIMUM 
to A 0> CO O to 
o o o o o o o 
Figure 4. Degradation of PAI-1 mRNA. 
CCL 64 cells were incubated in DUE with 0.2% 
calf serum. After incubation with 10 ng/itil 
TPA for two hours, cordycepin (15 ng/ml), 
actinomycin D (5 /xg/ml) , or cordycepin plus 
cycloheximide (10 jug/ml) were added (zero 
time). Total cellular RNAs were isolated at 
the specified times after zero time, resolved 
by agarose gel electrophoresis, and analyzed 
by Northern blot (10 fig RNA/lane) . The probes 
were^^P-labeled PAI-1 and 18S ribosomal 
RNA probes. Autoradiograms were analyzed by 
laser densitometry. To control for loading of 
total RNA, the intensity of the signal from 
PAI-1 mRNA was normalized with intensity of 
signal from 18S ribosomal RNA. 
The results are from two separate experiments. 
Top panel: Effects of actinomycin D, cyclohe­
ximide, cordycepin on PAI-1 mRNA degradation 
within 2 hours of their addition. 
Bottom panel: Effects of actinomycin D, cycl­
oheximide on PAI-1 mRNA degragation during a 
7 hour period after their addition. 
Cord./CHX. (-+-); Act D (-0-); Cord. (-?-); 
Cord./Act D (-*•-) . 
mRNA, INTENSITY mRNA, INTENSITY 
DISCUSSION 
Biosynthesis of PAI-1 is regulated in cultured cells by 
growth factors, tumor promoters and hormones. These agents 
are known to stimulate PAI-1 synthesis by increasing PAI-1 
gene transcription. For example, TGF-p, TNF-a and LPS in­
crease PAI-1 gene transcription in bovine aortic endothelial 
cells (36), TPA increase PAI-1 gene transcription in human 
rhabdomyosarcoma cells (24) and dexamethanone activate PAI-1 
gene in human fibrosarcoma cells (31). As well as gene tran­
scription, regulation of mRNA stability is a very important 
means of controlling the rate of protein accumulation and the 
steady state levels of mRNAs in cells (38, 7, 32). Here we 
show that the expression of PAI-1 in mink lung CCL64 epithe­
lial cells is governed both by increased synthesis after 
induction and the high turnover rate of its mRNA. 
We have found that the TPA induced PAI-1 mRNA in CCL64 
cells has a half life of about 25 min. Thus PAI-1 mRNA in 
CCL64 cells has a faster turnover rate than most mRNA in 
eukaryotic cells (43). The high turnover rate is an important 
factor that determines the brief time span of accumulation of 
PAI-1 mRNA in CCL64 cells. In these cells the PAI-1 mRNA 
rapidly accumulates to its maximum 3 hour after induction and 
declines to basal levels after 7 hour. The profile of mRNA 
accumulation is followed in time by a similar profile of the 
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production of secreted PAI-1 protein. The production of se 
creted PAI-1 increases to a maximum at 6-10 hour and returns 
to its basal level about 18 hour after the cells were treated 
with TPA. 
The rate of PAI-1 mRNA turnover is decreased by cyclo-
heximide and actinomycin D. These effects have been reported 
for other mRNAs. For example, actinomycin D stabilizes the 
mRNA of a cytokine gene, gro (45). Actinomycin D and cyclo-
heximide prevent the decay of mRNA encoding the transferrin 
receptor (26) , truncated c-fos (41), and c-myc (49) . A model 
that has been proposed to explain the effects of actinomycin 
D and cycloheximide (45, 26, 41) involves a labile factor 
encoded by a rapidly turning over mRNA that is involved in 
regulating degradation of selected mRNAs. In this model 
Actinomycin D and cycloheximide stabilize specific mRNAs by 
blocking synthesis of the labile factor. Our results can not 
support this model for PAI-1 mRNA because cordycepin, another 
transcriptional inhibitor, does not stabilize the PAI-1 mRNA. 
An alternate model (5) which has been postulated to explain 
the ability of cycloheximide to stabilize the mRNA of induci­
ble early response genes was that the degradation of these 
mRNAs is associated with translation. In this model Cyclo­
heximide blocks translational elongation by inhibiting the 
peptidyl transferase activity of the 60S ribosomal subunit 
and prevents degradation of the mRNA. We propose that actino-
34 
mycin D may also stabilize PAI-1 mRNA by blocking transla­
tion. Actinomycin D is reported to inhibit binding of mRNAs 
to ribosomes (43, 42). Actinomycin D is known to bind mRNAs 
in vitro and in vivo (47). Therefore it is possible that the 
PAI-1 mRNA is prevented from binding to ribosomes after 
intercalation of actinomycin D into the secondary structure 
of PAI-1 mRNA. 
To test the possibility that cordycepin promotes PAI-1 
mRNA degradation by facilitating the removal of the polyade-
nylated tail, the stabilization effect of actinomycin D was 
tested in the presence of cordycepin. That the same stabili­
zation effect of actinomycin D was observed indicated that 1) 
cordycepin does not decrease the stability of PAI-1 mRNA, and 
2) the stabilizing effect of actinomycin D is posttranscrip-
tional. In bovine aortic endothelial cells (36) the half-life 
of LPS, TGF-/3 and EGF induced PAI-1 mRNA was determined to be 
2.2 hour. In human hepatoma cells (48) the half-lives of TGF-
P and EGF induced PAI-1 mRNA were reported to be 3.1 hour and 
2.3 hour respectively. However, in these experiments actino­
mycin D was used to block PAI-1 gene transcription. Results 
reported in this work indicate that PAI-1 mRNA has a shorter 
half-life in mink lung CCL64 cells compared to that in bovine 
aortic cells and human hepatoma cells or that the half-life 
of PAI-1 mRNA was misinterpretated by the previous investiga­
tors because they used actinomycin D as the transcriptional 
blocking agent. 
35 
Our results describe several interesting features of PAI-
1 mRNA including it's inducibility, high turnover rate and 
stabilization by cycloheximide and actinomycin D. A group of 
mRNAs from transiently expressed genes of cytokines and 
oncogenes also share these features. A conserved AUUUA se­
quence at the 3' untranslated region of these mRNAs was found 
to mediate mRNA degradation (39). Although this AU-rich 
sequence is not found in PAI-1 mRNA, a related GU-rich se­
quence is localized in the 3' untranslated region. A similar 
GU-rich sequence was found in the 3' LTR of type 1 human T 
cell leukemia virus. This region is believed to direct cleav­
age of the viral pre-mRNA (1). The GU-rich sequence in PAI-1 
mRNA may also direct an endonucleolytic cleavage that renders 
the mRNA susceptible to further degradation. Besides the GU-
rich sequence, a previously identified 120 bp, highly con­
served sequence was found in the 3'-untranslated region. The 
significance of this high conservation is not yet clear but 
it is expected that this region must participate in some 
specific function because it has been maintained so faithful­
ly through mammalian evolution. 
In summary, we have demonstrated that PAI-1 mRNA has a 
very short half-life in mink lung CCL64 epithelial cells. The 
fast turnover rate of PAI-1 mRNA is consistent with the brief 
period of expression of the PAI-1 gene after the cells are 
stimulated by TPA. Analysis of the PAI-1 cDNA sequence iden­
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tified regions that may be important for the regulation of 
mRNA degradation. These results also show that PAI-1 mRNA 
turns over considerably faster then previously reported. The 
rapid rate of mRNA degradation allows rapid changes in the 
amount of PAI-1 secreted by cells in response to specific 
stimuli during events such as fibrinolysis, cellular migra­
tion, and tissue remodeling. 
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ABSTRACT 
Plasminogen activator inhibitor type 1 (PAI-1) is a serine 
protease inhibitor with a molecular weight about 50 kD. 
Because of its ability to control the activity of plasminogen 
activator (PA) and therefore the activation of plasmin, PAI-1 
is proposed to mediate functions of growth factors. 
The production of secreted PAI-1 is induced by transform­
ing growth factor-beta (TGF-jS) in mink lung CCL64 epithelial 
cells. Epidermal growth factor (EGF) interacts synergisti-
cally with TGF-/3 to increase PAI-1 expression in these cells 
to a level that is significantly higher than after stimula­
tion by TGF-)3 alone. The individual and synergistic effects 
of EGF and TGF-/3 are observed at the mRNA level. Transforming 
growth factor-/? increased the rate of PAI-1 gene transcrip­
tion. However, TGF-# and EGF did not activate PAI-1 gene 
transcription synergistically. The half life of PAI-1 mRNA is 
30 min in cells treated with TGF-/3 and 46 min in cells treat­
ed with TGF-j9 and EGF. It is concluded that the synergistic 
effect of TGF-/3 and EGF on PAI-1 induction is due to a combi­
nation of transcriptional activation by TGF-0 and stabiliza­
tion of PAI-1 mRNA by EGF. 
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INTRODUCTION 
Plasminogen activator inhibitor type 1 (PAI-1) is a 
glycoprotein with molecular weight of 50 kD and is present in 
plasma and platelets (1,2). Plasminogen activator inhibitory 
activity is increased after major surgery (3), severe trauma, 
(3) and myocardial infarction (4). In healthy individuals the 
PA-inhibitory activity in plasma fluctuates diurnally (5). 
Clearance of PA-inhibitory activity from the circulation is 
rapid with a half life of 3.5 minutes and 7 minutes in rat 
(6) and rabbits (7), respectively. 
PAI-1 is a negative regulator of plasminogen activators. 
Interaction between PAI-1 and two distinct groups of plasmin­
ogen activator (urokinase-type plasminogen activator, and 
tissue type plasminogen activator)•is rapid with a second 
order rate constant between 10^-10® M~^s~^(8). Plasminogen 
activators are serine proteases that convert the zymogen 
plasminogen into plasmin. Plasmin, a broad spectrum serine 
protease, degrades fibrin and extracellular matrix proteins. 
Therefore by controlling the PA-plasmin proteolytic cascade, 
PAI-1 is a crucial component in the regulation of many bio­
logical processes which involve the construction of extracel­
lular matrices (9,10). Because of this property PAI-1 is 
proposed to mediate some of the effects of growth factors 
(11) . 
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Transforming growth factor-/? (TGF-/3) and epidermal 
growth factor (EGF) can influence the differentiation and 
proliferation of cells (12,13). A cellular response to a 
growth factor may be modified by the presence of another 
growth factor. For example, anchorage independent growth of 
rat kidney NRK cells is stimulated synergistically by TGF-/3 
and EGF (14). 
We found that the production of secreted PAI-1 is in­
creased by IGF-p in mink lung CCL64 epithelial cells (15). 
Epidermal growth factor increases PAI-1 expression in mink 
CCL64 cells to a level that is significantly higher than 
after stimulation by TGF-/3 alone. Synergistic induction of 
PAI-1 by TGF-)3 and EGF was also found in human hepatoma cells 
(16). Synergism allows cells to achieve a response which is 
not possible by stimulation with one growth factor alone. 
We conducted experiments to examine the mechanisms that 
govern the synergism between EGF and TGF-/3 on PAI-1 induction 
in CCL64 cells. The results indicate that a combination of 
transcriptional activation by TGF-/? and stabilization of PAI-
1 mRNA by EGF explains the synergistic effect. 
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MATERIALS AND METHODS 
Materials; TGF-/3s were purified from porcine platelets ac­
cording to the method of Assoian et. al. (17) and from bovine 
platelets with a modified method (manuscript in preparation). 
The concentration of TGF-)3 that produced 99% inhibition of 
^H-thymidine incorporation by mink lung CCL64 Cells was 
defined as 1 unit/ml. Cells have equal sensitivity in PAI-1 
induction to 1 unit/ml TGF-j0 from either porcine or bovine. 
Epidermal growth factor was from Collaborative Research. 12-
O-tetradecanoylphorbol-13-acetate (TPA) and cordycepin were 
from Sigma. a^^P-dCTP was from New England Nuclear. o^^p-UTP 
was from ICN. The Random Primer Labeling Kit was from Amer-
sham and the Zeta-probe nylon membrane was from Bio-Rad. All 
reagents were analytical grade or better. 
Cell Culture; The mink lung CCL64 epithelial cell line, was 
obtained from Dr. Robert Holley. Stock cell cultures were 
grown as monolayer on tissue culture dishes with Dulbecco-
Vogt's medium (DMEM) containing 0.45% glucose, 10% calf 
serum, 10 units/ml penicillin and 10 ug/ml streptomycin, at 
37°C, in a water saturated atmosphere with 13% CO2 in air. 
Preparation of cDNA probes ; A 1.5 kb mink PAI-1 cDNA (manu­
script in preparation) fragment corresponding to bases 150-
1691 was generated by digesting mink PAI-1 cDNA with Sma I. 
The fragment was resolved by agarose gel electrophoresis, and 
isolated by the glass bead affinity adsorption method (Gene-
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clean, BIO 101 Inc.). To make the probe, the isolated cDNA 
fragment was radiolabeled with a^^P-dCTP to a specific radio­
activity about 1 X 10^ cpm/Mg using the random primer exten­
sion method. 
Preparation of total RNA. Northern blot, and hvbridization; 
Mink lung CCL64 cells were grown in DME medium with 0.2% calf 
serum for 24 hours. The cells were stimulated for two hours 
with different agents as indicated for individual experi­
ments. In some experiments, cordycepin was added to determine 
the decay rate of the induced mRNA. The cells were then 
washed twice with Tris-buffered salts (0.14 m NaCl, 5 mM KCl, 
0.68 mM CaClg, 0.49 mM MgCl2, 0.70 mM Na2HP02, 25 mM Tris-
HCl pH 7.1) and lysed with 4 M guanidinium isocyanate, 25 mM 
sodium acetate pH 6. The total RNA was separated from the 
cell lysate by isopycnic centrifugation in 5.7 M cesium 
chloride, 25 mM sodium acetate (18). After several rinses 
with 70% ethanol to remove the cesium chloride, the RNA was 
resuspended in 0.3 M sodium acetate pH 6, and preserved at 
-75°C. Electrophoresis of RNA through 1% agarose-formaldehyde 
gels was performed by using 1 mM EDTA, 5 mM sodium acetate, 
20 mM MOPS (3-[N-morpholino] propanesulfonic acid), pH 6 as 
running buffer. Northern blots were performed by transferring 
the RNA to nylon membranes in 50 mM sodium hydroxide. The RNA 
on the blots was hybridized with radiolabeled mink PAI-1 
probe for 18 h at 47°C in hybridization buffer (40% forma-
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mide, 7% SDS, 1% polyethylene glycol MW=20000, 0.25% non-fat 
milk, 0.6 M NaCl, 4 mM EDTA-Na2, 50 nq/ml salmon sperm DNA, 
40 mM NaH2P04, pH 7.5). The blots were washed in a solution 
of 30 mM NaCl, 0.2% SDS, 3 mM sodium citrate, pH 7 twice for 
15 min at 47°C. The blots were then exposed to Kodak XAR film 
at -75°C with two intensifying screens. To control the load­
ing of RNA samples, the blots were stripped in 0.1 % SDS, 10 
mM NaCl, 1.5 mM sodium citrate, at 80°C for 30 min twice and 
rehybridized with radiolabelled 18 S ribosomal RNA probe 
(19). The densities of autoradiographic signals were quanti­
fied by scanning densitometry (Zeinth model 504 XL). The 
density of signal from PAI-1 mRNA was normalized to the 
density of signal from 18 S ribosomal RNA in each sample. 
Nuclear run-on assay; Nuclear run-on was performed as de­
scribed by Greenberg and Ziff (20). Briefly, confluent mink 
lung CCL64 cells were grown in DME medium with 0.2% calf 
serum in two 15 cm diameter plates for 24 hours. The cells 
were treated for two hours with growth factors and other 
reagents as described in individual experiments. Nuclei from 
stimulated and control cells were isolated by lysing the cell 
pellet with NP-40 lysis buffer II (10 mM NaCl, 3 mM MgClg, 
0.5% NP-40, 10 mM Tris HCl, pH 7.4) and centrifuged at 2000 x 
g for 5 min. The supernatant was removed and the lysis proce­
dure was repeated once. The nuclei were suspended in 200 jul 
glycerol 
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storage buffer (5 mM MgClg, 0.1 mM EDTA, 40% glycerol, 50 
Tris HCl pH 8.3), mixed with an equal volume of 2 x reaction 
buffer (5 mM MgClg, 0.3 M KCl, 1 mM each of ATP, CTP, GTP, 
0.165 mM (500 /liCi/ml) ^^P-UTP (3000 mCi/mmole) , 50 mM Tris 
HCl pH 8.0) and incubated 30 min at 30°C to continue tran­
scription in vitro. The radiolabelled RNA was isolated and 
1x10® cpm were used for hybridization with 10 jug linearized 
mink PAI-1 cDNA fixed on nylon membranes. The hybridization 
solution was 40% formamide, 7% SDS, 1% polyethyleneglycol 
MW=20000, 0.25% non-fat milk, 0.6M NaCl, 40 mM NaHgPO^, 4 mM 
EDTA and 100 /xg/ml wheat germ tRNA. Hybridization performed 
at 47°C for 4 days. The membrane was washed to a final strin­
gency 0.2 X SSC, 0.2% SDS twice for 15 min at 47°C, and 
analyzed with a Phosphorimager (Molecular Dynamics). The 
signal intensity of PAI-1 was normalized to the signal inten­
sity from P65D5 cDNA (21) which was used as a loading control 
after the signal intensity of an equal amount of linearized 
pBluescript SK vector was substracted as background. 
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RESULTS 
EGF and TGF-8 synergisticallv regulate PAI-1 production: 
Growth factor- and mitogen-induced PAI-1 synthesis in cul­
tured cells is generally preceded by an increase in the 
steady state level of PAI-1 mRNA (22,23,24). To determine 
whether the synergism between TGF-/3 and EGF is also evident 
at the level of mRNA, mink lung CCI 64 cells were treated 
with TPA, EGF, TGF-)0 or EGF plus TGF-jS for 2 hours. Total 
RNAs were then isolated and a Northern blot was performed. 
Figure 1 shows that the accumulation of PAI-1 mRNA changes in 
parallel with the level of the secreted PAI-1 protein. These 
results also show that the synergistic effect of EGF and TGF-
13 occurs at the mRNA level. 
Transcriptional activity of the PAI-1 gene is not svnergisti-
callv induced by TGF-fl and EGF: To determine whether the 
synergism between EGF and TGF-/3 in increasing the level of 
PAI-1 mRNA occurs at the transcriptional level, the activa­
tion of the PAI-1 gene was studied with nuclear run-on exper­
iments. The results showed that TGF-j3 and EGF increased the 
transcriptional activity of PAI-1 gene but although EGF 
caused a significant increase in PAI-1 transcription in TGF-^S 
stimulated cells there was no synergism between EGF and TGF-^ 
in stimulating the transcription. (Figure 2) 
EGF stabilizes PAI-1 mRNA; The observation that TGF-^ and EGF 
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do not act synergistically to increase the transcriptional 
activity of the PAI-1 gene suggested that the TGF-p induced 
PAI-1 mRNA is stabilized in response to EGF. We tested this 
possibility by determining the effect of EGF on the decay 
rate of PAI-1 mRNA from CCL64 cells. The PAI-1 mRNA has a 
half-life of 30 min in cells treated with TGF-p whereas its 
half-life is 46 min in cells treated with EGF and TGF-/3 
(Figure 3). Statistical test by using Analysis of Variance 
(SAS, 1986) with P < .05 indicates that the difference be­
tween these two half-lives are significant. It is concluded 
that EGF stabilizes PAI-1 mRNA in CCL64 cells. 
Figure 1. Induction of PAI-1 itiRNA in CCL64 cells. 
A: CCL64 cells were cultured in DME medium with 
0.2% calf serum for 24 hours, then stimulated 
with 1 unit/ml TGF-)9, 5ng/ml EGF, 10 ng/ml TPA 
or EGF plus TGF-/3 for 2 hours. After incubat­
ion, total RNA were isolated. Equal amounts of 
total RNA (10 ng) were resolved by formaldehyde-
agarose gel electrophoresis. After blotting to 
a nylon membrane, the blot was hybridized with 
radiolabeled PAI-1 and 18 S ribosomal RNA probes. 
After exposure to X-ray film, the fluorogram was 
analyzed by laser densitometry. To control for 
loading of total RNA, the intensity of signal 
from PAI-1 mRNA was normalized with the inte­
nsity of signal from 18S ribosomal RNA in each 
samples. 
The result of PAI-1 mRNA is from an average of 
two separate experiments. The two experiments 
are normalized with the value from TGF-/3 plus 
EGF induced PAI-1 mRNA in each experiment. 
The data for PAI-1 protein production is taken 
from previously published results(15). 
C, control; E, EGF; T, TGF-j3. 
Protein (s^ ) ; mRNA (eS3 ) . 
B: Northern blot exposures that were used to obtain 
the data. 
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Figure 2. The effect of EGF and TGF-/3 on PAI-1 gene 
transcription. 
Transcriptional activity of the PAI-1 gene was 
determined by the nuclear runon assay. CCL64 
cells were incubated in DME medium with 0.2% 
calf serum. Nuclei were isolated 2 hours after 
the addition of 10 ng/ml TPA, 1 unit/ml IGF-p, 
5 ng/ml EGF or combination of TGF-/3 and EGF. 
Transcriptional runon was performed and the 
nascent RNA transcripts were isolated. Nylon 
filters with absorbed linearized plasmid were 
hybridized to the radiolabeled runon transcr­
ipts. The amount of radioactivity associated 
with each DNA plasmid was analyzed with Phos-
phoimager. The signal intensity of PAI-1 was 
normalized to signal intensity from P65D5 
cDNA (21) after substracting the signal 
intensity from pBluescript SK vector which was 
as back ground. 
Table: The results is from an average of 
three separate experiments. These experiments 
are normalized with the value of TGF-j3 plus 
EGF induced PAI-1 gene transcriptional acti­
vity in each experiments. 
A statistical comparsion was done by the 
Student's T test with P < .05. A significant 
difference was shown between transcriptional 
activity of the PAI-1 gene induced by TGF-p and 
by TGF-)9+EGF. 
Figure: Results from one experiment in which 
induction of PAI-1 mRNA and PAI-1 gene trans­
criptional activity were measured simutanously. 
C, control; E, EGF; T, TGF-/3. 
mRNA ( EEsa ) ; Gene transcriptional Activity ( ) . 
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Additions fold increase in PAI-1 
gene transcriptional activity 
— 
1.00 ± 1.00 
EGF 2.33 ± 1.22 
TGF-/3 3.14 ± 0.08 
EGF+TGF-P 4.00 ± 0.00 
TPA 8.00 ± 2.60 
E T T+E TPA 
Figure 3. The half life of PAI-1 mRNA in cells induced 
by TGF-p and EGF plus TGF-/3. 
CCL64 cells cultured in DME medium with 0.2% 
calf serum were incubated with 1 unit/ml TGF-^ 
and EGF (5 ng/ml) plus TGF-/3 for 2 hours. Cor-
dycepin (15 ug/ml) was then added (zero time) 
to block transcription. Total RNA was isolated 
at specific times and 10 total RNA loaded in 
each lane of 1% agarose-formaldehyde gel. The 
Northern blots were probed with radiolabelled 
PAI-1 and 18 S ribosomal RNA probe. After 
exposure to X-ray film, the autoradiograms were 
analyzed with laser densitometry. The intensity 
of signal from PAI-1 mRNA was normalized with the 
intensity of signal from 18S ribosomal RNA. 
The results were from two separate experiments. 
The half life of PAI-1 mRNA in TGF-/3 treated 
cells is 30 min (regression coefficient from a 
least squares analysis = 0.991). The half life 
of PAI-1 mRNA in TGF-/3 plus EGF treated cells is 
46 min (regression coefficient from a least 
squares analysis = 0.993). 
When tested by using Analysis of Variance (SAS, 
1986) the difference between these two lines were 
found to be significant to the level of P < 0.05. 
TGF-j9 + EGF (-0-) ; TGF-/3 ( - A - ) .  
mRNA, log(intensity) 
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DISCUSSION 
Epidermal growth factor and TGF-/3 synergistically induce 
PAI-1 synthesis in mink lung CCL64 cells (15). Synergism 
between TGF-/3 and EGF has been observed in other instances. 
For example, rat NRK cells are stimulated to grown in soft 
agar only in the presence of both EGF and TGF-/3 but not by 
TGF-p alone (14). 
TGF-p alters the number of high affinity EGF receptors 
in cultured rat heart endothelial cells (25). Expression of 
EGF induced c-myc, JE and KG genes are decreased by TGF-/3 
treatment in cultured mink BALB/MK cells (26) . TGF-f3 and EGF 
synergistically increase the transcriptional activity of the 
EGF receptor gene in human mammary carcinoma MDA 468 cells 
(27) and the fibronectin, cytosketal-j8 and T-actin genes in 
mouse AKR-2B cells (28). Increased EGF binding affinity is 
not responsible for the synergistic effect of TGF-p and EGF 
on PAI-1 induction in mink lung CCL64 cells, since TGF-/3 has 
no influence on the EGF binding affinity in these cells (29). 
In our study, it was found that the level of PAI-1 mRNA 
increased in parallel with the level of PAI-1 protein after 
mink CCL 64 cells are treated with EGF, TGF-/3, and their 
combination. Further investigation with nuclear runon assays 
showed that transcriptional activity of the PAI-1 gene was 
1.3 fold increased in cells treated with EGF plus TGF-jS com­
pared to cells treated with TGF-p alone. The half life of 
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GENERAL SUMMARY 
Previous studies from this laboratory indicate that the 
synthesis of plasminogen activator inhibitor type 1 (PAI-1), 
is highly regulated in cultured mink lung CCL64 epithelial 
cells. Transforming growth factor-^ (TGF-)3) increases the 
production of secreted PAI-1 to its maximal level at 5 to 7 
hours after induction. The secretion then returns to its 
basal level by 18 hours after addition of TGF-/3. Epidermal 
growth factor (EGF) and TGF-fS synergistically regulate the 
synthesis of PAI-1 (34). This study was conducted to under­
stand the mechanism by which PAI-1 is regulated in these 
cells and to reveal the mechanism of synergistic effect. 
Mink PAI-1 cDNA was cloned for the following reason. To 
compare with PAI-1 cDNA from different species, to search the 
potential determinant regions for mRNA turnover and for using 
as a probe to detect PAI-1 mRNA and PAI-1 genomic clone. 
A mink PAI-1 cDNA library with 1x10® original clones was 
constructed in Zap II vector from poly (A"*")-mRNA. The mRNA was 
isolated from TPA stimulated mink lung CCL64 cells. A mink 
PAI-1 clone with 2.97 kb insert was isolated by screening the 
library with radiolabeled human PAI-1 cDNA probe. The isolat­
ed clone was sequenced and characterized by analysis with the 
aid of computer program (68). A 68 bp 5'-nontranslated leader 
sequence, 1200 bp coding region and 1720 bp 3'-nontranslated 
region are coded by the cDNA. The coding region can be trans­
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lated into a peptide with 400 amino acids. A 379 amino acid 
mature peptide is preceded with a 21 amino acid signal pep­
tide. Compared to the PAI-1 sequence from other species, the 
entire amino acid sequence of mink PAI-1 is 86%, 87%, 79% and 
77% identical to human (21), bovine (23), mouse (67) and rat 
(22) respectively. Two amino acids in the signal peptide of 
mink PAI-1 were missing. Residues of the active center 
(Arg367-Met368) and three potential N-glycosylation sites are 
conserved. The missing two amino acids in the signal peptide 
obviously are not essential for secretion of mink PAI-1, 
because mink PAI-1 is secreted into the culture medium by 
mink lung CCL64 epithelial cells (34). 
Two potential important regions from the 3'-untranslated 
region of mink PAI-1 mRNA were identified. One is a 12 0 bp 
highly conserved region, the other is a GU-rich region. The 
highly conserved region has a 88-95% identical compared to 
the equivalent regions in the bovine (23), mouse (67), human 
(21) and rat (22) cDNAs. The significance of this high con­
servation in the 3'-untranslated region is unclear but it can 
be expected that this region contains some specific functions 
for the sequence to be maintained so faithfully through 
mammalian evolution. The second region, the GU-rich sequence, 
may play an important role in mRNA degradation since this 
sequence shows high identity to the GT-rich sequence on type 
1 human T cell leukemia virus 3' LTR (69). The T cell leuke­
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mia virus LTR GT rich region directs its pre-mRNA cleavage 
and facilitates polyadenylation. 
The post-transcriptional regulation of PAI-1 gene in 
mink lung CCL64 cells was studied. TPA induces the production 
of secreted PAI-1 to its maximum at 6-10 hours and the pro­
duction declined rapidly to its basal level by 18 hours. TPA 
induced PAI-1 mRNA to its maximum at 3 hours and the amount 
of PAI-1 mRNA then decreased to its basal level by 7 hours. 
The parallel changes in the time courses of protein produc­
tion and mRNA accumulation suggest that the level of PAI-1 
mRNA determines the production of secreted PAI-1. The time 
span for PAI-1 mRNA accumulation in mink lung CCL64 cells is 
much shorter than was reported for bovine aortic cells (65). 
In bovine aortic cells, PAI-1 mRNA is induced by TGF-/Î, TNF-a 
and LPS to its maximum at 12 hours and returns to its basal 
level by 48 hours. The half life of PAI-1 mRNA is about 30 
min in mink lung CCL64 cells treated with TPA or TGF-/3. This 
is shorter than the average half-life of mRNA in eukaryotic 
cells (70). 
Several features of PAI-1 mRNA are that it is inducible, 
has a high turnover rate and is stabilized by cycloheximide 
and actinomycin D. The same properties were found for the 
mRNA of truncated c-fos (71) and c-myc (72) . One mechanism 
often cited to explain the stabilization effect of actionomy-
cin D is that the degradation of mRNA involves a labile 
factor and actinomycin D blocks the transcription of the 
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factor therefore stabilizing the mRNA (73,74). However, our 
results can not suport this model since cordycepin does not 
stabilize PAI-1 mRNA. Cordycepin is a inhibitor of transcrip­
tion that should have the same effect as actinomycin D in 
blocking the synthesis of proposed labile factor. We proposed 
that the degradation of PAI-1 mRNA in mink lung CCL64 cells 
is translation associated (75). Actinomycin D is proposed to 
prevent degradation of PAI-1 mRNA by preventing its transla­
tion. It has been found that actinomycin D can bind mRNA in 
vitro and in vivo (76) and inhibit the binding of mRNA to 
ribosomes (77,78). 
The synergistic effect of PAI-1 induction was studied. 
In mink lung CCL64 cells, TGF-)3 and EGF synergistically 
induced PAI-1 to a level that is significantly higher than 
expected from the sum of EGF and TGF-/3 alone. 
The steady state level of PAI-1 mRNA increases in paral­
lel with the production of secreted PAI-1 in cells treated 
with EGF, TGF-)0, and the combination of both. This result 
indicates that the synergism occurred at the level of mRNA 
accumulation. The nuclear runon assays indicate that TGF-/3 
and EGF increase the transcriptional activity of PAI-1 gene, 
however the PAI-1 gene is not synergistically induced by EGF 
plus TGF-p. The half-life of PAI-1 mRNA in cells treated with 
EGF and TGF-/3 is 46 min. The half-life of PAI-1 mRNA in cells 
treated with TGF-j0 is 30 min. These results indicate that the 
72 
synergistic effect of these growth factors in PAI-1 expression 
is the result of a combination of transcriptional activation 
of PAI-1 gene by TGF-/3 and the PAI-1 mRNA stabilization by 
EGF. 
Mechanisms for controlling mRNA degradation in eukaryot-
ic cells have been described. One example is the degradation 
of histone mRNA. Histone mRNA is degraded by a ribosome-
associated exonuclease (79). This nuclease is activated by 
interaction with a factor that recognize the stem loop struc­
ture at the 3' terminus of histone mRNA. Stabilization of 
transferrin receptor mRNA presents another example. An iron 
response element (IRE) in the 3' untranslated region of this 
mRNA determines the stability of the mRNA (73). The IRE 
contains five approximately 30 bp imperfectly repeated se­
quences. Binding of a 90 kD protein to this element stabi­
lizes the mRNA while dissociation of the 90 kD protein causes 
the destabilization on the transferrin receptor mRNA (80). 
Another example is the degradation of tubulin mRNA. The first 
13 translated bases of this mRNA codes for a tetra peptide, 
Met-Arg-Glu-Ile. It is this region that autoregulates its own 
mRNA stability (81). The mode of tubulin mRNA degradation is 
that a ribonuclease is activated after binding of unassembled 
dimers of o:- and ^-tubulin to the nascent amino acid terminal 
of ^-tubulin. The activated ribonuclease then degrades the 
ribosome-bound ^-tubulin mRNA (82). An other mechanism which 
controls mRNA degradation is mediated by an AU-rich sequence 
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at the 3'-untranslated end of mRNA coding for proto-oncogenes, 
lymphokines and cytokines (83). Messenger RNA encoding pro­
teins in these classes usually have short half lives of 15-30 
min. A protein factor of 34 kD which binds to the AU-rich 
sequence has been isolated (84, 85). The AU sequence in c-fos 
and c-myc is necessary but not sufficient for mRNA degrada­
tion. Another sequence in the coding region is also necessary 
for the mRNA instability (71,72). One interesting aspect is 
that all the mRNA degradation mechanisms described above, 
except for the transferrin receptor mRNA, are believed to be 
translationally related. 
Of these mRNAs described above, the c-myc and c-fos mRNA 
share many of the same features as PAI-1 mRNA. They are 
inducible, have high turnover rates and are stabilized by 
cycloheximide. Truncated fos and myc mRNAs are also stabi­
lized by actinomycin D. The GU-rich region in PAI-1 mRNA may 
direct its mRNA degradation as AU-rich sequence does for c-
fos and c-myc mRNAs. 
The next step for this research is to identify the 
regions of PAI-1 mRNA that regulate its degradation. This can 
be done by making deletion constructions of mink PAI-1 cDNA 
in an expression vector, express the construct in cells and 
determine half-lives of the expressed mRNA from each con­
struct. 
In summary, these studies have revealed that the 
74 
control of PAI-1 mRNA degradation in mink lung CCL64 cells is 
crucial in determining the extent and profile of expression 
of the PAI-1 gene. The GU-rich region and the 120 bp high 
conserved region identified in the 3'-untranslated region of 
mink PAI-l mRNA might be important in the regulation of PAI-1 
mRNA degradation. EGF stabilizes PAI-1 mRNA in mink lung 
CCL64 epithelial cells. 
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